title: The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C.
abstract: Morphologic characteristics of the graft have been proposed as a major contributor to the long-term outcomes in orthotopic liver transplantation (OLT). Our objective was to determine the impact of donor variables, including donor age, donor-recipient HLA match, and type of donation (DCD vs donation after brain death [DBD]), on the outcome of OLT in 192 patients with hepatitis C virus (HCV). Fourteen patients underwent OLT from donation after cardiac death (DCD) donors and 188 from DBD donors. Mean donor age, warm ischemia time at recovery, and cold ischemia time were similar between the groups. Overall graft survival rate at 1 year (55% DCD vs 85% DBD) and 5 years (46% DCD vs 78% DBD) was significantly lower in the DCD group (P = .0003). Similarly, patient survival rate at 1 year (62% DCD vs 93% DBD) and 5 years (62% DCD vs 82% DBD) was significantly lower in the DCD group (P = .0295). Incidences of hepatic artery thrombosis, portal vein thrombosis, and primary nonfunction were similar between the DCD and DBD groups. The incidence of liver abscess with ischemic-type biliary stricture was higher in recipients from DCD as compared with DBD (42% vs 2%). A trend toward lower graft survival was noted in recipients from donors older than 60 years of age in the HCV population (P = .07), with statistically lower patient survival (P = .02). Donor- recipient HLA matching did not appear to correlate with OLT outcome in patients with HCV. DCD donors and donors older than 60 years of age significantly impact patient and graft survival. Lower graft and patient survival in recipients from DCD donors does not appear to be related to early disease recurrence.
authors.affiliation: Division of Transplantation, University of Wisconsin, Madison, WI, USA; Gulhane Military Medical Academy, Ankara, Turkey.
authors.forename: G
authors.initials: G
authors.lastname: Yagci
authors.forename: L A
authors.initials: LA
authors.lastname: Fernandez
authors.forename: S J
authors.initials: SJ
authors.lastname: Knechtle
authors.forename: A M
authors.initials: AM
authors.lastname: D'Alessandro
authors.forename: L T
authors.initials: LT
authors.lastname: Chin
authors.forename: A I
authors.initials: AI
authors.lastname: Musat
authors.forename: M R
authors.initials: MR
authors.lastname: Lucey
authors.forename: A
authors.initials: A
authors.lastname: Said
authors.forename: J D
authors.initials: JD
authors.lastname: Pirsch
authors.forename: G
authors.initials: G
authors.lastname: Leverson
authors.forename: M
authors.initials: M
authors.lastname: Kalayoglu
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002102:Cadaver; D005260:Female; D006085:Graft Survival; D006526:Hepatitis C / Q000601:surgery*; D006801:Humans; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D014019:Tissue Donors / Q000706:statistics & numerical data*; D016896:Treatment Outcome
chemical_list: D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase